Hospital

Currently, the drug will be studied in the SKYBRIDGE (NCT05652686) trial, a first-in-human, phase 1/2, open-label, dose-escalation and expansion study.

Noticing indicators of IVIG non-responsiveness can lead to better outcomes among patients with Kawasaki disease as treatment is adjusted.

Craig Beavers discusses significance of the 2024 update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure.

CAR T-cell therapy in multiple myeloma faces challenges from the immunosuppressive cells in the tumor microenvironment.

The updates are based on nationwide reports of extreme pain during IUD insertion.

AI and other technologies, in conjunction with ASHP’s guidelines, can improve drug diversion monitoring and outcomes.

Investigators analyzed a series of disease-modifying therapies in a multi-decade trial.

The hemostatic gel is plant-based and designed to stop and control bleeding within seconds after applied to wound at the point of care.

The current outbreak has infected more than 14,000 people and spread to 13 different African countries.

RSV and influenza vaccines demonstrated hemagglutination inhibition titers that were noninferior to those with sequential administration.

Kelsea Seago, PharmD, discusses the crucial role of pharmacists in managing chimeric antigen receptor (CAR) T-cell therapy resistance.

The supplemental biologics license application was granted based on results from the ADRIATIC phase 3 trial among individuals with limited stage small cell lung cancer.

The decision is based positive data from the Deltacel-01 clinical trial.

AC699 is being evaluated for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2–), estrogen receptor 1-mutated advanced or metastatic breast cancer with disease progression on or after at least 1 line of endocrine-based therapy.

The new prices are expected to go into effect for patients with Medicare Part D on January 1, 2026.

Axatilimab-csfr (Niktimvo, Incyte Corporation) is a colony stimulating factor-1 receptor-blocking antibody for the treatment of chronic graft-versus-host disease (cGVHD).

The decision is based on clinical findings demonstrating seladelpar’s ability to effectively regulate of alkaline phosphatase values in patients.

Response to intravenous immunoglobulin treatment and analysis of neurofilament light chains in patients could be used as prognostic indicators of Guillain-Barre syndrome.

Individuals with Parkinson disease reported a decrease in bacterial genes for biosynthesis of riboflavin (vitamin B2) and biotin (vitamin B7).

The seroprotection rate of antibody titers was 100% against the 3 viruses, and geometric mean titer also increased from administration to day 43.

Predicting disease progression is essential to improve the health outcomes of patients with multiple sclerosis.

In recent years, telestroke services have transformed stroke care delivery, especially in rural or underserved areas.

Pharmacists play an important role in managing patients with this complex condition.

Community accessibility and specialized training in effective medication counseling make pharmacists a valuable resource in helping address injectable biologic hesitancy.

The study may serve as a foundation for future investigation regarding dietary recommendations to support the treatment of Alzheimer disease.

The autologous, fully human CD19 chimeric antigen receptor T-cell product, KYV-101, is being studied for the treatment of patients with progressive myasthenia gravis.

Risk of developing anxiety or depression is highest within the first year after cardiovascular hospitalization.

The systematic review summarized all available evidence on the subject, finding that intravenous immunoglobulin could have a role in treatment.

Palopegteriparatide is a prodrug of parathyroid hormone designed to provide continuous exposure of the hormone over a 24-hour dosing period.

Many patients are unaware of wound complication, so it is valuable for pharmacists to communicate prevention methods with all patients with diabetes.